Related Experiment Video

Updated: Oct 5, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor?

C Fabrizi1, R Businaro, G M Lauro

  • 1Department of Biology, University 'Roma Tre', Rome, Italy. fabrizi@uniroma3.it

Journal of Neurochemistry
|July 20, 2001
PubMed

Insights

Alpha-2 macroglobulin (alpha2M) has a dual role in Alzheimer's disease, acting as a neuroprotectant or neurotoxin. Its effect depends on the presence of its receptor, low-density lipoprotein receptor-related protein (LRP).

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Alpha-2 macroglobulin (alpha2M) is a key protein involved in beta-amyloid (Abeta) clearance and aggregation.
  • The alpha2-macroglobulin receptor/low density lipoprotein receptor related protein (LRP) mediates the cellular uptake of alpha2M/Abeta complexes.
  • Impaired LRP function is implicated in Alzheimer's disease pathogenesis.

Purpose of the Study:

  • To elucidate the contradictory roles of alpha2M in Abeta-induced neurotoxicity.
  • To investigate the influence of LRP expression levels on alpha2M's neurotoxic or neuroprotective effects.

Main Methods:

  • Utilized human neuroblastoma cell lines with varying LRP expression levels.
  • Administered activated alpha2M in combination with Abeta.
  • Assessed cell viability and apoptosis using MTT and TUNEL assays.
  • Employed recombinant proteins to identify the specific neurotoxic fragment of alpha2M.

Main Results:

  • In LRP-positive cells, activated alpha2M demonstrated neuroprotective effects against Abeta toxicity.
  • In LRP-negative cells, activated alpha2M exacerbated Abeta-induced neurotoxicity.
  • Re-expression of LRP in negative cells restored the neuroprotective function of alpha2M.
  • The FP3 fragment of alpha2M was identified as responsible for its neurotoxic activity.

Conclusions:

  • Alpha2M exhibits both neuroprotective and neurotoxic properties in the context of Abeta exposure.
  • The cellular receptor LRP critically regulates the neuroprotective or neurotoxic outcome of alpha2M.
  • Targeting LRP may offer a therapeutic strategy for modulating alpha2M's role in Alzheimer's disease.

More Related Videos

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils00:15

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...